Ketamine is used as an anesthetic to put patients to sleep during surgery and medical procedures. In recent years, it has also been used in small doses to treat severe depression and chronic pain when other treatments haven't worked.[2] Ketalar is currently approved and in use across 126 indications[4].[1]
Ketalar is one of 1808 small molecule programs targeting ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
2828 competitors in Breast Cancer
Ketalar
Halaven
Tecentriq
Cymbalta
Lexiscan
Adenocard
MS Contin
Spravato
Sporanox
Chirocaine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
KETALAR
NDA NDA016812
Sources
Details